Get the Stockscreener App
2.62
4.38%
0.11
After Hours:
2.62
Eledon Pharmaceuticals Inc stock is traded at $2.62, with a volume of 1.04M.
It is up +4.38% in the last 24 hours and up +32.99% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$2.51
Open:
$2.54
24h Volume:
1.04M
Relative Volume:
1.30
Market Cap:
$208.63M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.4637
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+8.26%
1M Performance:
+32.99%
6M Performance:
-3.32%
1Y Performance:
-33.50%
1-Day Range:
$2.52
$2.72
1-Week Range:
$2.42
$2.72
52-Week Range:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.62 | 199.87M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - Bitget
ELDN SEC FilingsEledon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Aug Opening: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Trade Ideas & Free Reliable Trade Execution Plans - baoquankhu1.vn
Aug Gainers: Whats Eledon Pharmaceuticals Incs historical returnBond Market & Daily Stock Trend Watchlist - baoquankhu1.vn
ELDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
What makes Eledon Pharmaceuticals Inc. stock attractive todayGlobal Markets & High Accuracy Trade Signal Alerts - mfd.ru
Will Eledon Pharmaceuticals Inc. stock deliver shareholder valueWeekly Investment Summary & Long-Term Safe Investment Ideas - mfd.ru
What’s the beta of Eledon Pharmaceuticals Inc. stock2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Can Eledon Pharmaceuticals Inc. expand its profit marginsGap Down & Free High Return Stock Watch Alerts - mfd.ru
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference - MarketBeat
Eledon Pharmaceuticals at Guggenheim Summit: Tegoprubart’s Promising Path By Investing.com - Investing.com Canada
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Sahm
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Eledon Pharmaceuticals drops 10% on stock offering - MSN
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Up 3.6% – Should You Buy? - Defense World
Eledon Pharmaceuticals: Sustained Tegoprubart Efficacy, Differentiated Safety, and Upcoming Transplant Catalysts Support Buy Rating - TipRanks
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - Sahm
Eledon reports positive 24-month kidney transplant data for tegoprubart By Investing.com - Investing.com India
Eledon Pharmaceuticals restructures stake via pre-funded warrant - MSN
Craig-Hallum Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating - 富途资讯
Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter Symposium - marketscreener.com
Eledon Pharmaceuticals (ELDN) to Reveal Promising Kidney Transpl - GuruFocus
Eledon reports positive 24-month kidney transplant data for tegoprubart - Investing.com
2-year transplant data: Eledon's tegoprubart shows no rejection in 8 patients - stocktitan.net
Surprises Report: Is SDHC stock a value trapEarnings Overview Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Loss Report: Is Eledon Pharmaceuticals Inc stock a good dividend stock2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Growth Value: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
What Caused Eledon Pharmaceuticals Stock (ELDN) to Drop 50% Today? - Intellectia AI
Patterns Watch: Is AVAH forming a double bottomWeekly Trend Recap & Smart Investment Allocation Tips - baoquankhu1.vn
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Price Target from Analysts - Defense World
Buy Signal: Will Eledon Pharmaceuticals Inc stock deliver better than expected guidanceJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - Bộ Nội Vụ
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Eledon Pharmaceuticals Shares Sink After Announcing $50 Million Public Offering - MSN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - The Manila Times
Profit Review: Can Eledon Pharmaceuticals Inc. stock sustain market leadershipQuarterly Portfolio Report & Stepwise Swing Trade Plans - ulpravda.ru
Can Eledon Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - Улправда
How Eledon Pharmaceuticals Inc. (2TK) stock trades after earningsQuarterly Earnings Report & Community Verified Trade Signals - ulpravda.ru
Eledon’s tegoprubart shows promise in kidney transplantation trials By Investing.com - Investing.com South Africa
Eledon’s tegoprubart shows promise in kidney transplantation trials - Investing.com
Can Eledon Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Update & Verified Entry Point Signals - Улправда
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):